Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class, ...

Negeri Sembilan Menteri Besar Aminuddin Harun has taken a swipe at several NGOs said to be lobbying for Port Dickson’s name to be changed to Pantai Dermaga in a bid to shed its colonial links. “I was ...

A Malaysian beach resort won a prize at the recent World Luxury Hotel Awards 2016 held in Doha. The Avillion Port Dickson emerged as winner in the Luxury Spa Hotel category for Malaysia. The ...

Malaysia’s over dependence on the Klang Valley’s congested ports is pushing its logistics network to the brink. With roads perpetually gridlocked and land for essential services rapidly shrinking, the ...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, ...

Tenaga Nasional Berhad (TNB) has confirmed a fire has broken out at the Tuanku Jaafar Power Plant in Port Dickson, Negeri Sembilan, but assured that the situation is under control. It said a technical ...

Malaysian infrastructure firm Gamuda is moving into data centers and acquired a plot outside Kuala Lumpur that could reportedly support up to 1GW of capacity. Last week the company announced its ...

SEREMBAN, Jan 1 (Bernama) -- The Port Dickson Army Museum has introduced entry fees for visitors starting today, ending 19 years of free admission since its establishment. In a notice shared on its ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis Phase IIIb clinical development of Airsupra was conducted by Avillion under an ...

London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca’s Airsupra (albuterol/budesonide) in patients with ...

The trial, which was conducted by Avillion under an exclusive clinical co-development agreement with AstraZeneca, included patients with intermittent or mild persistent asthma, including those on ...